The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells-Reference-Cited by-同舟云学术

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells

Published:2017-06-05 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Castella Barbara,Kopecka Joanna,Sciancalepore Patrizia,Mandili Giorgia,Foglietta Myriam,Mitro Nico^ORCID,Caruso Donatella,Novelli Francesco^ORCID,Riganti Chiara^ORCID,Massaia Massimo

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms15663.pdf

Reference55 articles.

1. Gober, H. J. et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163–168 (2003).

2. Roelofs, A. J., Thompson, K., Gordon, S. & Rogers, M. J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12, 6222s–6230s (2006).

3. Castella, B. et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells. J. Immunol. 187, 1578–1590 (2011).

4. Harly, C., Peigné, C. M. & Scotet, E. Molecules and mechanisms implicated in the peculiar antigenic activation process of human Vγ9Vδ2 T Cells. Front. Immunol. 5, 657 (2015).

5. Fiore, F. et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110, 921–927 (2007).

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphoantigen recognition by Vγ9Vδ2 T cells;European Journal of Immunology;2024-08-15

2. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer;Journal of Experimental & Clinical Cancer Research;2024-08-07

3. Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy;2024-07-11

4. Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy;Autoimmunity Reviews;2024-06

5. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy;Science Advances;2024-03-15